Oxidized alginate hydrogels for bone morphogenetic protein-2 delivery in long bone defects

Acta Biomaterialia

Volumn 10, Issue 10, 2014, Pages 4390-4399

  Priddy, Lauren B ^a   Chaudhuri, Ovijit ^b   Stevens, Hazel Y ^c   Krishnan, Laxminarayanan ^a   Uhrig, Brent A ^a,c   Willett, Nick J ^a,c   Guldberg, Robert E ^a,c  

^a GEORGIA INSTITUTE OF TECHNOLOGY   (United States)

^b Stanford University   (United States)

^c GEORGIA INSTITUTE OF TECHNOLOGY   (United States)

Author keywords

Alginate; Bioactivity; BMP 2 (bone morphogenetic protein 2); Bone regeneration; Oxidation

Indexed keywords

ALGINATE; BIOCOMPATIBILITY; BONE; COMPUTERIZED TOMOGRAPHY; DEFECTS; DEGRADATION; HYDROGELS; PHOSPHATASES; TISSUE ENGINEERING;

ALGINATE HYDROGELS; BONE DEFECT; BONE FRACTURE; BONE MORPHOGENETIC PROTEIN-2; BONE REGENERATION; IN-VIVO; LONG BONE; MATURE BONE; OXIDIZED ALGINATES;

OXIDATION;

ALGINIC ACID; ALKALINE PHOSPHATASE; NANOFIBER; RECOMBINANT BONE MORPHOGENETIC PROTEIN 2; BMP2 PROTEIN, HUMAN; BONE MORPHOGENETIC PROTEIN 2; GLUCURONIC ACID; HEXURONIC ACID; HYDROGEL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BIOLOGICAL ACTIVITY; BIOMECHANICS; BONE DEFECT; BONE REGENERATION; DRUG RELEASE; ENZYME ACTIVITY; FEMALE; HISTOPATHOLOGY; HYDROGEL; IN VITRO STUDY; IN VIVO STUDY; IRRADIATION; LONG BONE; MICRO-COMPUTED TOMOGRAPHY; MICRORADIOGRAPHY; NONHUMAN; OXIDATION; RAT; ANIMAL; CELL LINE; CHEMISTRY; CONGENITAL MALFORMATION; DISEASE MODEL; DRUG DELIVERY SYSTEM; DRUG EFFECTS; FEMUR; HUMAN; MOUSE; OXIDATION REDUCTION REACTION; PATHOLOGY; PHARMACOLOGY; SPRAGUE DAWLEY RAT; TIME;

ALGINATES; ANIMALS; BONE MORPHOGENETIC PROTEIN 2; BONE REGENERATION; CELL LINE; DISEASE MODELS, ANIMAL; DRUG DELIVERY SYSTEMS; FEMALE; FEMUR; GLUCURONIC ACID; HEXURONIC ACIDS; HUMANS; HYDROGELS; MICE; OXIDATION-REDUCTION; RATS; RATS, SPRAGUE-DAWLEY; TIME FACTORS;

EID: 84908253852     PISSN: 17427061     EISSN: 18787568     Source Type: Journal    
DOI: 10.1016/j.actbio.2014.06.015     Document Type: Article

References (46)

1. E.A. Finkelstein, P.S. Corso, and T.R. Miller Incidence and economic burden of injuries in the United States 2006 Oxford University Press New York
2. A. Praemer, S. Furner, and D.P. Rice Musculoskeletal conditions in the United States 1999 American Academy of Orthopaedic Surgeons Rosemont, Illinois
3. C. Laurencin, Y. Khan, and S.F. El-Amin Bone graft substitutes Expert Rev Med Devices 3 2006 49 57
4. R.C. Sasso, J.C. LeHuec, and C. Shaffrey Iliac crest bone graft donor site pain after anterior lumbar interbody fusion: a prospective patient satisfaction outcome assessment J Spinal Disord Tech 18 2005 S77 S81
5. H. Seeherman, J. Wozney, and R. Li Bone morphogenetic protein delivery systems Spine 27 2002 S16 S23
6. M. Lind, E.F. Eriksen, and C. Bunger Bone morphogenetic protein-2 but not bone morphogenetic protein-4 and -6 stimulates chemotactic migration of human osteoblasts, human marrow osteoblasts, and U2-OS cells Bone 18 1996 53 57
7. E.A. Wang, D.I. Israel, S. Kelly, and D.P. Luxenberg Bone morphogenetic protein-2 causes commitment and differentiation in C3Hl0T1/2 and 3T3 cells Growth Factors 9 1993 57 71
8. J.M. Wozney The bone morphogenetic protein family and osteogenesis Mol Reprod Dev 32 2005 160 167
9. J.R. Lieberman, A. Daluiski, and T.A. Einhorn The role of growth factors in the repair of bone J Bone Joint Surg 84 2002 1032 1044
10. A. Nauth, B. Ristevski, R. Li, and E.H. Schemitsch Growth factors and bone regeneration: how much bone can we expect? Injury 42 2011 574 579
11. M.F. Swiontkowski, H.T. Aro, S. Donell, J.L. Esterhai, J. Goulet, and A. Jones Recombinant human bone morphogenetic protein-2 in open tibial fractures. A subgroup analysis of data combined from two prospective randomized studies J Bone Joint Surg 88 2006
12. K.S. Cahill, J.H. Chi, A. Day, and E.B. Claus Prevalence, complications, and hospital charges associated with use of bone-morphogenetic proteins in spinal fusion procedures JAMA 302 2009 58 66
13. L.B. Shields, G.H. Raque, S.D. Glassman, M. Campbell, T. Vitaz, and J. Harpring Adverse effects associated with high-dose recombinant human bone morphogenetic protein-2 use in anterior cervical spine fusion Spine 31 2006 542 547
14. R.D. Dickerman, A.S. Reynolds, B.C. Morgan, J. Tompkins, J. Cattorini, and M. Bennett Rh-BMP-2 can be used safely in the cervical spine: dose and containment are the keys! Spine J 7 2007 508 509
15. A.D. Augst, H.J. Kong, and D.J. Mooney Alginate hydrogels as biomaterials Macromol Biosci 6 2006 623 633
16. W.R. Gombotz, and S. Wee Protein release from alginate matrices Adv Drug Deliv Rev 31 1998 267 285
17. K.Y. Lee, M.C. Peters, K.W. Anderson, and D.J. Mooney Controlled growth factor release from synthetic extracellular matrices Nature 408 2000 998 1000
18. C.A. Simmons, E. Alsberg, S. Hsiong, W.J. Kim, and D.J. Mooney Dual growth factor delivery and controlled scaffold degradation enhance in vivo bone formation by transplanted bone marrow stromal cells Bone 35 2004 562 569
19. J.A. Rowley, G. Madlambayan, and D.J. Mooney Alginate hydrogels as synthetic extracellular matrix materials Biomaterials 20 1999 45 53
20. M.S. Shoichet, R.H. Li, M.L. White, and S.R. Winn Stability of hydrogels used in cell encapsulation: an in vitro comparison of alginate and agarose Biotechnol Bioeng 50 1996 374 381
21. J.E. Babensee, J.M. Anderson, L.V. McIntire, and A.G. Mikos Host response to tissue engineered devices Adv Drug Deliv Rev 33 1998 111 139
22. E. Alsberg, H.J. Kong, Y. Hirano, M.K. Smith, A. Albeiruti, and D.J. Mooney Regulating bone formation via controlled scaffold degradation J Dent Res 82 2003 903 908
23. T. Boontheekul, H.J. Kong, and D.J. Mooney Controlling alginate gel degradation utilizing partial oxidation and bimodal molecular weight distribution Biomaterials 26 2005 2455 2465
24. K.H. Bouhadir, K.Y. Lee, E. Alsberg, K.L. Damm, K.W. Anderson, and D.J. Mooney Degradation of partially oxidized alginate and its potential application for tissue engineering Biotechnol Prog 17 2001 945 950
25. H.J. Kong, D. Kaigler, K. Kim, and D.J. Mooney Controlling rigidity and degradation of alginate hydrogels via molecular weight distribution Biomacromolecules 5 2004 1720 1727
26. E.A. Silva, and D.J. Mooney Spatiotemporal control of vascular endothelial growth factor delivery from injectable hydrogels enhances angiogenesis J Thromb Haemost 5 2007 590 598
27. J.D. Boerckel, K.M. Dupont, Y.M. Kolambkar, A.S. Lin, and R.E. Guldberg In vivo model for evaluating the effects of mechanical stimulation on tissue-engineered bone repair J Biomech Eng 131 2009 084502
28. J.D. Boerckel, Y.M. Kolambkar, K.M. Dupont, B.A. Uhrig, E.A. Phelps, and H.Y. Stevens Effects of protein dose and delivery system on BMP-mediated bone regeneration Biomaterials 32 2011 5241 5251
29. Y.M. Kolambkar, K.M. Dupont, J.D. Boerckel, N. Huebsch, D.J. Mooney, and D.W. Hutmacher An alginate-based hybrid system for growth factor delivery in the functional repair of large bone defects Biomaterials 32 2011 65 74
30. M.E. Oest, K.M. Dupont, H.J. Kong, D.J. Mooney, and R.E. Guldberg Quantitative assessment of scaffold and growth factor-mediated repair of critically sized bone defects J Orthop Res 25 2007 941 950
31. W.S. Kim, D.J. Mooney, P.R. Arany, K. Lee, N. Huebsch, and J. Kim Adipose tissue engineering using injectable, oxidized alginate hydrogels Tissue Eng A 18 2012 737 743
32. J.D. Boerckel Mechanical regulation of bone regeneration and vascular growth in vivo 2011 Georgia Institute of Technology
33. M. Wiemann, H.M. Rumpf, D. Bingmann, and H.P. Jennissen The binding of rhBMP-2 to the receptors of viable MC3T3-E1 cells and the question of cooperativity Materialwiss Werkst 32 2001 931 936
34. J. Patterson, R. Siew, S.W. Herring, A.S. Lin, R. Guldberg, and P.S. Stayton Hyaluronic acid hydrogels with controlled degradation properties for oriented bone regeneration Biomaterials 31 2010 6772 6781
35. J.N. Zara, R.K. Siu, X. Zhang, J. Shen, R. Ngo, and M. Lee High doses of bone morphogenetic protein 2 induce structurally abnormal bone and inflammation in vivo Tissue Eng A 17 2011 1389 1399
36. S. Chubinskaya, K. Huch, M. Schulze, L. Otten, M.B. Aydelotte, and A.A. Cole Gene expression by human articular chondrocytes cultured in alginate beads J Histochem Cytochem 49 2001 1211 1219
37. J.O. You, S.B. Park, H.Y. Park, S. Haam, C.H. Chung, and W.S. Kim Preparation of regular sized Ca-alginate microspheres using membrane emulsification method J Microencapsul 18 2001 521 532
38. How can I convert an RGB image to grayscale but keep one color? < http://stackoverflow.com/questions/4063965/how-can-i-convert-an-rgb-image-to-grayscale-but-keep-one-color >.
39. Y.M. Kolambkar, J.D. Boerckel, K.M. Dupont, M. Bajin, N. Huebsch, and D.J. Mooney Spatiotemporal delivery of bone morphogenetic protein enhances functional repair of segmental bone defects Bone 49 2011 485 492
40. O. Jeon, S.J. Song, H.S. Yang, S.H. Bhang, S.W. Kang, and M.A. Sung Long-term delivery enhances in vivo osteogenic efficacy of bone morphogenetic protein-2 compared to short-term delivery Biochem Biophys Res Commun 369 2008 774 780
41. K.V. Brown, B. Li, T. Guda, D.S. Perrien, S.A. Guelcher, and J.C. Wenke Improving bone formation in a rat femur segmental defect by controlling bone morphogenetic protein-2 release Tissue Eng A 17 2011 1735 1746
42. B. Li, T. Yoshii, A.E. Hafeman, J.S. Nyman, J.C. Wenke, and S.A. Guelcher The effects of rhBMP-2 released from biodegradable polyurethane/microsphere composite scaffolds on new bone formation in rat femora Biomaterials 30 2009 6768 6779
43. M.C. Peters, B.C. Isenberg, J.A. Rowley, and D.J. Mooney Release from alginate enhances the biological activity of vascular endothelial growth factor J Biomater Sci Polym Ed 9 1998 1267 1278
44. B. Rai, S.H. Teoh, D.W. Hutmacher, T. Cao, and K.H. Ho Novel PCL-based honeycomb scaffolds as drug delivery systems for rhBMP-2 Biomaterials 26 2005 3739 3748
45. R.H. Li, and J.M. Wozney Delivering on the promise of bone morphogenetic proteins Trends Biotechnol 19 2001 255 265
46. M.R. Urist Bone: formation by autoinduction Science 150 1965 893 899